Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

121. Clinically Localized Prostate Cancer

Clinically Localized Prostate Cancer Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.00606 Journal of Clinical Oncology - published online before print (...) September 5, 2018 PMID: Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline x Justin E. Bekelman , x R. Bryan Rumble , x Ronald C. Chen , x Thomas M. Pisansky , x Antonio Finelli , x Andrew Feifer , x Paul L. Nguyen , x D. Andrew Loblaw , x Scott T. Tagawa , x Silke Gillessen , x Todd M. Morgan , x Glenn Liu , x Neha Vapiwala , x John J. Haluschak , x Andrew

2018 American Society of Clinical Oncology Guidelines

122. ASTRO/AUA Guideline on Hypofractionation for Localized Prostate Cancer

ASTRO/AUA Guideline on Hypofractionation for Localized Prostate Cancer Supplemental Materials for Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 6, Pages 354–360 Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA (...) period for guideline), Bayer (Joint Safety Review Committee; ended during disclosure period for guideline); Per Halvorsen: American College of Radiology Radiation Oncology Practice Accreditation program (honoraria, travel expenses); Karen Hoffman: Vanderbilt University (consultant); Patrick Greany: Department of Defense Prostate Cancer Research Program (research funding, honoraria, travel expenses); Bridget Koontz: Janssen (research funding), Blue Earth Diagnostics (advisory board), American Society

2018 American Society for Radiation Oncology

123. Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT

Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you (...) need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Randomisation of men to a RCT comparing partial prostate ablation and radical prostatectomy is feasible. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Freddie C Hamdy 1, * , Daisy Elliott 2 , Steffi le Conte 1 , Lucy C Davies 3 , Richéal M Burns 3 , Claire Thomson 1 , Richard Gray 3 , Jane Wolstenholme 3 , Jenny L Donovan 2, 4 , Ray Fitzpatrick 3 , Clare Verrill 1 , Fergus

2018 NIHR HTA programme

124. Prostate cancer

Prostate cancer Prostate cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Prostate cancer Last reviewed: February 2019 Last updated: September 2018 Summary Second leading cause of cancer mortality in men in the US. Uncommon in men aged under 50 years. Prostate-specific antigen and digital rectal examination are key diagnostic tools used in screening. Management may be expectant or definitive. In the US, overall (...) 5-year survival rate is around 100% for local- and regional-stage prostate cancer, and around 30% for distant-stage prostate cancer (based on data from 2007 to 2013). Definition A malignant tumour of glandular origin, situated in the prostate. It is most commonly seen in older men; between 2011 and 2015 the median age at diagnosis in the US was 66 years. National Cancer Institute; Surveillance, Epidemiology, and End Results program (SEER). SEER stat fact sheets: prostate cancer. 2018 [internet

2018 BMJ Best Practice

125. Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP) (PubMed)

Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP) Health research in low- and middle-income countries can generate novel scientific knowledge and improve clinical care, fostering population health improvements to prevent premature death. Project management is a critical part of the success of this research, applying knowledge, skills, tools, and techniques to accomplish required goals. Here, we describe (...) the development and implementation of tools to support a multifaceted study of prostate cancer in Africa, focusing on building strategic and operational capacity.Applying a learning organizational framework, we developed and implemented a project management toolkit (PMT) that includes a management process flowchart, a cyclical center-specific schedule of activities, periodic reporting and communication, and center-specific monitoring and evaluation metrics.The PMT was successfully deployed during year one

Full Text available with Trip Pro

2018 Journal of global oncology

126. Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (PubMed)

Development, Evaluation, and Implementation of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate Cancer of the prostate (CaP) is the leading cancer among men in sub-Saharan Africa (SSA). A substantial proportion of these men with CaP are diagnosed at late (usually incurable) stages, yet little is known about the etiology of CaP in SSA.We established the Men of African Descent and Carcinoma of the Prostate Network, which includes seven SSA centers (...) 95% of tested DNA samples (100% from blood-derived DNA samples) with high concordance across laboratories.We provide approaches that can produce high-quality epidemiologic and genomic data in multicenter studies of cancer in SSA.

Full Text available with Trip Pro

2018 Journal of global oncology

127. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry (PubMed)

Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry There is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, sequencing information can be derived from large, real-world registry studies.PROXIMA (Treatment (...) Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy) is a large, global, prospective registry study evaluating real-world treatment patterns of patients with mCRPC who experience disease progression during or after docetaxel therapy. Patients were enrolled worldwide between 2011 and 2014. Treatments were determined by the treating physicians and recorded in categories of chemotherapy, hormonal therapy, targeted therapy

Full Text available with Trip Pro

2018 Journal of global oncology

128. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. (PubMed)

Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to screen for prostate cancer.Systematic review and meta-analysis.Electronic search of Cochrane Central Register of Controlled Trials, Web of Science, Embase, Scopus, OpenGrey, LILACS, and Medline, and search of scientific meeting abstracts and trial registers to April 2018.Randomised controlled trials (...) mortality (IRR 0.99, 95% CI 0.98 to 1.01; moderate certainty) and may have no effect on prostate-specific mortality (IRR 0.96, 0.85 to 1.08; low certainty). Sensitivity analysis of studies at lower risk of bias (n=1) also demonstrates that screening seems to have no effect on all-cause mortality (IRR 1.0, 0.98 to 1.02; moderate certainty) but may have a small effect on prostate-specific mortality (IRR 0.79, 0.69 to 0.91; moderate certainty). This corresponds to one less death from prostate cancer per

Full Text available with Trip Pro

2018 BMJ

129. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment

Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment Report available from http://www.muhc.ca/tau Technology Assessment Unit of the McGill University Health Centre (MUHC) Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment Report number: 82 DATE: April 16, 2018 Report available from http://www.muhc.ca/tau Report prepared for the Technology Assessment Unit (TAU) of the McGill University (...) Health Centre (MUHC) by David Felipe Forero, Nisha Almeida, Nandini Dendukuri Approved by the Committee of the TAU on April 16 th , 2018 TAU Committee Andre Bonnici, James Brophy, Nandini Dendukuri, Todd Lee, Brenda MacGibbon-Taylor, Emily McDonald, Teresa Mack, Nancy Mayo, Maurice McGregor, Alyson Turner Suggested citation Forero DF, Almeida ND, Dendukuri N. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment. Montreal (Canada): Technology

2018 McGill TAU reports

130. Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value

Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value Evidence Report August 24, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page i Evidence Report - Antiandrogens for Nonmetastatic Castration-Resistant Prostate Cancer AUTHORS: ICER Staff/Consultants University (...) Report - Antiandrogens for Nonmetastatic Castration-Resistant Prostate Cancer About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation

2018 California Technology Assessment Forum

131. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment (PubMed)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment Purpose Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO ( ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis using a randomized, double-blind, placebo-controlled design. Patients and Methods In period one, men with chemotherapy (...) -naïve metastatic castration-resistant prostate cancer received open-label enzalutamide 160 mg daily. Men with no prostate-specific antigen (PSA) increase at weeks 13 and 21 were treated until PSA progression (≥ 25% increase and ≥ 2 ng/mL above nadir), then randomly assigned at a one-to-one ratio in period two to abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily with either enzalutamide or placebo (combination or control group, respectively) until disease progression as defined

Full Text available with Trip Pro

2018 EvidenceUpdates

132. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial Long-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) is a standard treatment for patients with localized high-risk prostate cancer (HRPC). However, the optimal duration of ADT is not yet defined.The aim of this superiority randomized trial was to compare outcomes of RT combined with either 36 or 18 mo of ADT.From October 2000 to January 2008, 630 patients with HRPC were (...) prostate cancer patients treated with radiotherapy and either 36 or 18 mo of androgen deprivation therapy. There was no difference in survival between the two groups, with the 18-mo group experiencing a better quality of life.Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2018 EvidenceUpdates

133. Prostate Cancer

Prostate Cancer Prostate Cancer | Uroweb › Prostate Cancer Prostate Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . N. Mottet (Chair), R.C.N. van den Bergh, E. Briers (Patient Representative), P. Cornford (Vice-chair), M. De Santis, S. Fanti, S. Gillessen, J. Grummet, A.M. Henry, T.B. Lam, M.D. Mason, T.H. van der Kwast, H.G. van der Poel, O. Rouvière, D. Tilki, T. Wiegel (...) Guidelines Associates: T. Van den Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, L. Moris, I.G. Schoots, P-P.M. Willemse TABLE OF CONTENTS REFERENCES 1. Drost, F.J.H., et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews, 2019. In press. 2. Van den Broeck, T., et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

2018 European Association of Urology

134. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study (PubMed)

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study Abiraterone acetate plus prednisone (AAP) and enzalutamide (ENZ) are commonly prescribed for metastatic castration-resistant prostate cancer (mCRPC). Data comparing their effects on patient-reported outcomes (PROs) from routine clinical practice are limited.AQUARiUS (NCT02813408 (...) ) is an ongoing, two-cohort, prospective, observational, non-randomised, multicentre, phase IV European study assessing the effects of AAP and ENZ on PROs in 211 patients with mCRPC over 12 months. Patients receive AAP or ENZ per routine clinical practice. Data on cognition, fatigue, pain and health-related quality of life are measured using the Functional Assessment of Cancer Therapy-Cognitive Function, Brief Fatigue Inventory-Short Form, Brief Pain Inventory-Short Form and European Organization for Research

Full Text available with Trip Pro

2018 ESMO open

135. Prostate cancer

Prostate cancer Top results for prostate cancer - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostate cancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

136. Prostate cancer screening

Prostate cancer screening Top results for prostate cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search (...) might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for prostate cancer screening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance

2018 Trip Latest and Greatest

137. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Adding multiparametric MRI as an initial test prior to prostate biopsy can reduce the proportion of men having unnecessary biopsies and improve the detection of clinically significant prostate cancer. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , & . Louise Clare Brown 1 , Hashim U Ahmed 2, 3, * , Rita

2018 NIHR HTA programme

138. Proteomics of prostate cancer – revealing how cancer cells master their messy genomes (PubMed)

Proteomics of prostate cancer – revealing how cancer cells master their messy genomes 30234142 2018 11 14 2331-4737 5 7-8 2018 Jul Oncoscience Oncoscience Proteomics of prostate cancer - revealing how cancer cells master their messy genomes. 216-217 10.18632/oncoscience.453 Latonen Leena L Leena Latonen: Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, Finland; FimLab laboratories, Tampere University Hospital (...) , Tampere, Finland. Nykter Matti M Leena Latonen: Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, Finland; FimLab laboratories, Tampere University Hospital, Tampere, Finland. Visakorpi Tapio T Leena Latonen: Prostate Cancer Research Center, Faculty of Medicine and Life Sciences and BioMediTech Institute, University of Tampere, Tampere, Finland; FimLab laboratories, Tampere University Hospital, Tampere, Finland. eng Journal

Full Text available with Trip Pro

2018 Oncoscience

139. Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking (PubMed)

Evaluating the potential benefit of reduced planning target volume margins for low and intermediate risk patients with prostate cancer using real-time electromagnetic tracking The aim of this study is to quantify and describe the feasibility, clinical outcomes, and patient-reported outcomes of reduced planning target volume (PTV) margins for prostate cancer treatment using real-time, continuous, intrafraction monitoring with implanted radiation frequency transponder beacons.For this prospective (...) (0.05 mm and 0.06 mm, respectively). At 6 months, patients demonstrated a smaller change in Expanded Prostate Cancer Index Composite scores than the ProtecT comparator group (decreased short-term morbidity). However, in the Bowel and Urinary domains at 12 and 24 months, there was no significant difference.Our data confirm and support that the use of Calypso tracking with intensity modulated radiation therapy reliably provides minimal disruption to daily treatments and overall time of treatment

Full Text available with Trip Pro

2018 Advances in radiation oncology

140. Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience (PubMed)

Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience Purpose Data on prostate cancer (PCa) treatment in Africa remains under-reported. We present a review of the management of PCa at the cancer center of the largest tertiary referral facility in Ghana, with emphasis on curative treatment. Methods We retrospectively reviewed data on 1,074 patients seen at the National Center for Radiotherapy and Nuclear Medicine from 2003 to 2016. Patient and disease (...) with localized disease received curative radiotherapy. The 5-year overall survival for the curative cohort was 96% (interquartile range, 93% to 98%). The 5-year bDFS rates for low-, intermediate-, and high-risk groups were 95%, 70%, and 48%, respectively. Both Gleason score and pretreatment prostate-specific antigen were significant predictors for bDFS in multivariable analysis. Conclusion We show that the majority of patients with PCa have locally advanced disease at the time of presentation

Full Text available with Trip Pro

2018 Journal of global oncology